Carbonyl stress in chronic renal failure: the effect of haemodialysis.
Oxidative stress has been defined as a loss of balance between free radical production and the antioxidant systems. There have been many reports of increased production of oxidants and decreased levels of antioxidants in chronic renal failure (CRF) patients. An increase in oxidative stress may contribute to the development of oxidative protein damage in CRF. Our aim was to reveal oxidative modifications of plasma proteins by measuring 2,4-dinitrophenylhydrazine reactive carbonyl derivates (PCO), protein thiol (P-SH) and reduced glutathione (GSH) in predialytic uraemic and haemodialysed (HD) patients before and after dialysis. We included 20 predialytic uraemic patients, 20 HD patients and 20 healthy volunteers in our study. PCO concentration in predialytic uraemic patients increased compared with the concentration of the control group and this increase was more profound in HD patients. P-SH concentrations were significantly decreased in haemodialytic patients compared with those of controls. GSH level was higher in HD patients (both before and after dialysis). Increased PCO and decreased P-SH concentrations in all patient groups in comparison to the control subjects indicate increased protein oxidation. Our data in ESRD patients propose plasma protein carbonyl derivates and thiol concentrations as novel specific markers for oxidative protein damage.
Dursun
Evrim
E
Department of Biochemistry, Akdeniz University Medical Faculty, 07070 Antalya, Turkey.
Dursun
Belda
B
Süleymanlar
Gültekin
G
Ozben
Tomris
T
D000368:Aged; D001798:Blood Proteins / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D010659:Phenylhydrazines / Q000737:chemistry / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects*; D013438:Sulfhydryl Compounds / Q000378:metabolism*; D014511:Uremia / Q000209:etiology / Q000378:metabolism* / Q000628:therapy
D001798:Blood Proteins; D010659:Phenylhydrazines; D013438:Sulfhydryl Compounds; C004787:2,4-dinitrophenylhydrazine; D005978:Glutathione